Richard J. Baum March 20, 2026
or more than a century, international drug control policy has relied on treaties designed primarily to regulate plant-based narcotics such as opium, coca, and cannabis. Today’s illicit drug market looks very different. Synthetic opioids, methamphetamine, and thousands of newly engineered psychoactive substances can now be produced almost anywhere using globally traded chemicals. Yet the international legal framework governing drug control has not kept pace with these changes.
This is not just a problem for the two most severely impacted countries—the United States and Canada—as other nations are also experiencing growing synthetic opioid problems. Addressing the volatile global market for synthetic opioids and other synthetic drugs will require intensified multilateral efforts, including new mechanisms for cooperation and more frequent opportunities to impose international controls on emerging drugs and precursor chemicals. The current system—under which governments meet once a year in Vienna at the Commission on Narcotic Drugs (CND) to consider new international controls—was designed for an earlier era and struggles to keep pace with today’s synthetic drug markets. During the CND’s regular session from March 9-13, two nitazenes and a synthetic cannabinoid were scheduled by the United Nations. Surely, before next year at this time, there will be new drug threats that deserve similar treatment.
The most recent international drug control treaty was adopted in 1988, well before the emergence of today’s synthetic substances and designer precursor chemicals. A newly negotiated global treaty focused squarely on synthetic drugs could provide modernized tools for more effective joint action. It would also send a clear signal to governments around the world about their responsibility to address the global illicit drug supply chain. As the global drug market evolves, the international legal framework governing it must evolve as well.
The scale and speed of change in the synthetic drug market raise an important question for policymakers: whether the existing international treaty framework can realistically keep pace with these developments. While the current conventions have long served as the backbone of international drug control, the rise of many new synthetic drugs and designer precursor chemicals suggests that new international mechanisms are necessary. This article examines recent synthetic drug trends, explains the limitations of the existing treaty system, and outlines several elements that could form the foundation of a new international agreement focused on synthetic drugs and their chemical inputs.
Synthetic drug trends
After years of truly stunning increases in fatal overdoses beginning around 2013 in the United States, it has been a relief to see large declines emerge over the past two years. Total drug overdose deaths, which peaked at 107,941 in 2022, have fallen to 68,408 over the most recent 12-month period, according to the Centers for Disease Control and Prevention (CDC). Although this decline is encouraging, overdose levels remain historically high, and addiction rates appear largely unchanged.
There has been considerable discussion about the causes of this decline. Some researchers attribute the decline to what they describe as a “fentanyl drought,” possibly linked to Chinese controls on precursor chemicals. Others point to additional factors, including expanded access to treatment, widespread naloxone distribution, the easing of social isolation during the COVID-19 pandemic, and possible strategic adjustments in fentanyl formulations by Mexican trafficking organizations.
If the reduction in fentanyl potency was driven primarily by Mexican cartel producers’ difficulty in obtaining sufficient high-quality precursor chemicals from China, the decline may prove temporary. Drug trafficking organizations are highly adaptive and continuously experiment with new production methods, chemical inputs, and drug formulations. Traffickers are already experimenting with alternative opioids, attempting to manufacture fentanyl precursors themselves, and seeking new sources of chemical inputs. Recent reporting indicates that Mexican criminal organizations have even begun recruiting chemistry students to assist in synthetic drug production.
Read more
